Dongah Kim
Dongah Kim has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Aimee Humphries
Department of Obstetrics, Gynaecology and Reproductive Sciences, FMHS; The University of Auckland; Auckland New Zealand
1 shared publication- Cindy Farquhar
Department of Obstetrics and Gynaecology; University of Auckland; Auckland New Zealand
1 shared publication Francesca Casciola
Department of Obstetrics, Gynaecology and Reproductive Sciences, FMHS; The University of Auckland; Auckland New Zealand
1 shared publicationMackenzie Ferguson
Department of Obstetrics, Gynaecology and Reproductive Sciences, FMHS; The University of Auckland; Auckland New Zealand
1 shared publicationMagdalena Bofill Rodriguez
Department of Obstetrics, Gynaecology and Reproductive Sciences; FMHS, The University of Auckland; Auckland New Zealand
1 shared publicationMichelle R Wise
Department of Obstetrics, Gynaecology and Reproductive Sciences, FMHS; The University of Auckland; Auckland New Zealand
1 shared publication
Latest Publications
- 23 October 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (10) , CD000402
Hormone therapy in postmenopausal women and risk of endometrial hyperplasia or endometrial cancer
Rationale Reduced circulating estrogen levels around the time of menopause can induce symptoms that affect health and well‐being. Estrogen therapy is the most effective treatment, but may be associated with some adverse health outcomes, including endometrial pathology. This is an update of a review first published in 1999 and last updated in 2012. Objectives • To assess the effects of hormone therapy regimens for protecting postmenopausal women against endometrial hyperplasia and endometrial cancer. • To define the lowest effective dose(s) of progestogen used in combination with estrogen therapy for protecting the endometrium. Search methods We searched for trials in the Cochrane Gynaecology and Fertility Group specialized register, CENTRAL (containing output from two trial registers and CINAHL), MEDLINE, Embase, and PsycINFO to 22 July 2024. We also checked references and contacted study authors to identify additional studies. Eligibility criteria Interventions of interest were unopposed estrogen, continuous combined estrogen and progestogen, and sequential combined estrogen and progestogen, administered for at least one year. These interventions could be compared head to head or with placebo. Trials had to report rates of endometrial hyperplasia or endometrial cancer (histologic diagnosis). Outcomes Our critical outcomes were endometrial hyperplasia and endometrial cancer at one year and after one year. Our important outcomes were adherence to therapy, requirement for additional interventions, and withdrawal due to adverse events. Risk of bias We used the original Cochrane risk of bias tool (RoB 1). Synthesis methods Where meta‐analysis was possible, we calculated odds ratios (ORs) with 95% confidence intervals (CIs). We used GRADE to assess the certainty of evidence for each outcome. Included studies This update included 72 studies (involving 40,652 women) conducted worldwide. There were 42 multicenter trials. Synthesis of results There were too few studies with events to draw conclusions about endometrial cancer. The results for endometrial hyperplasia are presented below. Unopposed estrogen versus placebo Unopposed estrogen probably increases the risk of endometrial hyperplasia at one year compared with placebo (22–43 events/1000 women versus 5 events/1000 women; OR 5.86, 95% CI 4.09 to 8.40; I² = 0%; 6 RCTs, 2493 women; moderate‐certainty‐evidence). Unopposed estrogen probably increases the risk of endometrial hyperplasia after one year (40–68 events/1000 women versus 6 events/1000 women; OR 8.97, 95% CI 6.78 to 11.87; I² = 49%; 9 RCTs, 2539 women; moderate‐certainty‐evidence). Continuous combined estrogen plus progestogen versus placebo Continuous combined therapy may have little to no effect on the risk of endometrial hyperplasia at one year compared with placebo (0–16 events/1000 women versus 5 events/1000 women; OR 0.51, 95% CI 0.08 to 3.38; I² = 48%; 4 RCTs, 3893 women; low‐certainty‐evidence). We are unsure about the effect of continuous combined therapy after one year (OR 0.25, 95% CI 0.04 to 1.40; I² = 47%; 4 RCTs, 789 women; very low‐certainty evidence). Sequential combined estrogen plus progestogen versus placebo Sequential combined therapy may increase the risk of endometrial hyperplasia at one year compared with placebo (6–27 events/1000 women versus 2 events/1000 women; OR 5.53, 95% CI 2.60 to 11.76; I² = 0%; 4 RCTs, 1030 women; low‐certainty‐evidence). Sequential combined therapy may result in little to no difference in the risk of endometrial hyperplasia after one year (16–97 events/1000 women versus 20 events/1000 women; OR 2.30, 95% CI 0.76 to 6.99; I² = 0%; 3 RCTs, 534 women; low‐certainty‐evidence). Unopposed estrogen versus continuous combined estrogen plus progestogen Unopposed estrogen probably increases the risk of endometrial hyperplasia at one year compared with continuous combined therapy (46–75 events/1000 women versus 3 events /1000 women; OR 21.90, 95% CI 16.76 to 28.62; I² = 53%; 11 RCTs, 7856 women; moderate‐certainty‐evidence). Unopposed estrogen probably increases the risk of endometrial hyperplasia after one year compared with continuous combined therapy (33–73 events/1000 women versus 3 events/1000 women; OR 16.78, 95% CI 11.01 to 25.55; I² = 69%; 3 RCTs, 1191 women; moderate‐certainty‐evidence). Unopposed estrogen versus sequential combined estrogen plus progestogen Unopposed estrogen may increase the risk of endometrial hyperplasia at one year compared with sequential combined therapy (156‐301 events/1000 women versus 16 events/1000 women; OR 17.19, 95% CI 11.27 to 26.22; I² = 70%; 5 RCTs, 2354 women; low‐certainty‐evidence). Unopposed estrogen may increase the risk of endometrial hyperplasia after one year compared with sequential combined treatment (379–612 events/1000 women versus 49 events/1000 women; OR 19.21, 95% CI 11.95 to 30.90; I² = 15%; 2 RCTs, 417 women; low‐certainty‐evidence). Continuous combined estrogen plus progestogen versus sequential combined estrogen plus progestogen All analyses had insufficient events to draw conclusions. Continuous combined estrogen plus progestogen – dose comparisons We are unsure about the effect of moderate‐dose estrogen plus low‐dose progestogen compared with moderate‐dose estrogen plus moderate‐dose progestogen on the risk of endometrial hyperplasia at one year (OR 1.18, 95% CI 0.24 to 5.84; I² = 36%; 2 RCTs, 2363 women; very low‐certainty‐evidence). The remaining dose comparisons had insufficient events to draw conclusions. Sequential combined estrogen plus progestogen – dose comparisons Moderate‐dose estrogen plus low‐dose progestogen may result in little to no difference in the risk of...
- 23 October 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (10) , CD000402
Hormone therapy in postmenopausal women and risk of endometrial hyperplasia or endometrial cancer
Rationale Reduced circulating estrogen levels around the time of menopause can induce symptoms that affect health and well‐being. Estrogen therapy is the most effective treatment, but may be associated with some adverse health outcomes, including endometrial pathology. This is an update of a review first published in 1999 and last updated in 2012. Objectives • To assess the effects of hormone therapy regimens for protecting postmenopausal women against endometrial hyperplasia and endometrial cancer. • To define the lowest effective dose(s) of progestogen used in combination with estrogen therapy for protecting the endometrium. Search methods We searched for trials in the Cochrane Gynaecology and Fertility Group specialized register, CENTRAL (containing output from two trial registers and CINAHL), MEDLINE, Embase, and PsycINFO to 22 July 2024. We also checked references and contacted study authors to identify additional studies. Eligibility criteria Interventions of interest were unopposed estrogen, continuous combined estrogen and progestogen, and sequential combined estrogen and progestogen, administered for at least one year. These interventions could be compared head to head or with placebo. Trials had to report rates of endometrial hyperplasia or endometrial cancer (histologic diagnosis). Outcomes Our critical outcomes were endometrial hyperplasia and endometrial cancer at one year and after one year. Our important outcomes were adherence to therapy, requirement for additional interventions, and withdrawal due to adverse events. Risk of bias We used the original Cochrane risk of bias tool (RoB 1). Synthesis methods Where meta‐analysis was possible, we calculated odds ratios (ORs) with 95% confidence intervals (CIs). We used GRADE to assess the certainty of evidence for each outcome. Included studies This update included 72 studies (involving 40,652 women) conducted worldwide. There were 42 multicenter trials. Synthesis of results There were too few studies with events to draw conclusions about endometrial cancer. The results for endometrial hyperplasia are presented below. Unopposed estrogen versus placebo Unopposed estrogen probably increases the risk of endometrial hyperplasia at one year compared with placebo (22–43 events/1000 women versus 5 events/1000 women; OR 5.86, 95% CI 4.09 to 8.40; I² = 0%; 6 RCTs, 2493 women; moderate‐certainty‐evidence). Unopposed estrogen probably increases the risk of endometrial hyperplasia after one year (40–68 events/1000 women versus 6 events/1000 women; OR 8.97, 95% CI 6.78 to 11.87; I² = 49%; 9 RCTs, 2539 women; moderate‐certainty‐evidence). Continuous combined estrogen plus progestogen versus placebo Continuous combined therapy may have little to no effect on the risk of endometrial hyperplasia at one year compared with placebo (0–16 events/1000 women versus 5 events/1000 women; OR 0.51, 95% CI 0.08 to 3.38; I² = 48%; 4 RCTs, 3893 women; low‐certainty‐evidence). We are unsure about the effect of continuous combined therapy after one year (OR 0.25, 95% CI 0.04 to 1.40; I² = 47%; 4 RCTs, 789 women; very low‐certainty evidence). Sequential combined estrogen plus progestogen versus placebo Sequential combined therapy may increase the risk of endometrial hyperplasia at one year compared with placebo (6–27 events/1000 women versus 2 events/1000 women; OR 5.53, 95% CI 2.60 to 11.76; I² = 0%; 4 RCTs, 1030 women; low‐certainty‐evidence). Sequential combined therapy may result in little to no difference in the risk of endometrial hyperplasia after one year (16–97 events/1000 women versus 20 events/1000 women; OR 2.30, 95% CI 0.76 to 6.99; I² = 0%; 3 RCTs, 534 women; low‐certainty‐evidence). Unopposed estrogen versus continuous combined estrogen plus progestogen Unopposed estrogen probably increases the risk of endometrial hyperplasia at one year compared with continuous combined therapy (46–75 events/1000 women versus 3 events /1000 women; OR 21.90, 95% CI 16.76 to 28.62; I² = 53%; 11 RCTs, 7856 women; moderate‐certainty‐evidence). Unopposed estrogen probably increases the risk of endometrial hyperplasia after one year compared with continuous combined therapy (33–73 events/1000 women versus 3 events/1000 women; OR 16.78, 95% CI 11.01 to 25.55; I² = 69%; 3 RCTs, 1191 women; moderate‐certainty‐evidence). Unopposed estrogen versus sequential combined estrogen plus progestogen Unopposed estrogen may increase the risk of endometrial hyperplasia at one year compared with sequential combined therapy (156‐301 events/1000 women versus 16 events/1000 women; OR 17.19, 95% CI 11.27 to 26.22; I² = 70%; 5 RCTs, 2354 women; low‐certainty‐evidence). Unopposed estrogen may increase the risk of endometrial hyperplasia after one year compared with sequential combined treatment (379–612 events/1000 women versus 49 events/1000 women; OR 19.21, 95% CI 11.95 to 30.90; I² = 15%; 2 RCTs, 417 women; low‐certainty‐evidence). Continuous combined estrogen plus progestogen versus sequential combined estrogen plus progestogen All analyses had insufficient events to draw conclusions. Continuous combined estrogen plus progestogen – dose comparisons We are unsure about the effect of moderate‐dose estrogen plus low‐dose progestogen compared with moderate‐dose estrogen plus moderate‐dose progestogen on the risk of endometrial hyperplasia at one year (OR 1.18, 95% CI 0.24 to 5.84; I² = 36%; 2 RCTs, 2363 women; very low‐certainty‐evidence). The remaining dose comparisons had insufficient events to draw conclusions. Sequential combined estrogen plus progestogen – dose comparisons Moderate‐dose estrogen plus low‐dose progestogen may result in little to no difference in the risk of...
- Open Access
Intrauterine insemination: a UK survey on the adherence to NICE clinical guidelines by fertility clinics
Objective To evaluate the awareness and response of fertility clinics in the UK to the National Institute for Health and Care Excellence (NICE) guideline recommendation that intrauterine insemination (IUI) should not be offered routinely, in order to report on current practice in the UK. Design Online questionnaire survey of fertility clinics in the UK regarding their current clinical practice of IUI, formal discussion of the guideline recommendations, and any alterations made since the recommendations. Setting 66 UK fertility clinics licensed to provide IUI. Participants 46 fertility clinics, including 6 clinic groups which represent 70% of all clinics and clinic groups licensed to provide IUI in April 2014 when the survey email was sent. Results Of the 46 clinics that responded, 96% (44/46) of clinics continue to offer IUI. 98% (43/44) of those offering IUI also use ovarian stimulation. The most commonly used medications for ovarian stimulation are gonadotrophins (95%), followed by clomiphene citrate (49%) and letrozole (19%). 78% (36/46) of clinics had formally discussed NICE guideline recommendations. 17 clinics (37%) had made some changes to their practices; as a result, four clinics reported a reduction in the number of IUI cycles, six clinics had restricted the indications for IUI, and five clinics had begun informing patients of the guideline recommendations, while two did not specify. Conclusions The majority of clinics were aware of the guideline recommendations. However, only a small proportion of clinics had made significant changes to their practice by reducing the number of IUI cycles or restricting the clinical indications for IUI. The availability of further evidence will assist NICE and clinicians in making recommendations on the use of IUI. There is a need to further explore the reasons for the lack of adherence to the recommendations.
Open AccessIntrauterine insemination: a UK survey on the adherence to NICE clinical guidelines by fertility clinics
Objective To evaluate the awareness and response of fertility clinics in the UK to the National Institute for Health and Care Excellence (NICE) guideline recommendation that intrauterine insemination (IUI) should not be offered routinely, in order to report on current practice in the UK. Design Online questionnaire survey of fertility clinics in the UK regarding their current clinical practice of IUI, formal discussion of the guideline recommendations, and any alterations made since the recommendations. Setting 66 UK fertility clinics licensed to provide IUI. Participants 46 fertility clinics, including 6 clinic groups which represent 70% of all clinics and clinic groups licensed to provide IUI in April 2014 when the survey email was sent. Results Of the 46 clinics that responded, 96% (44/46) of clinics continue to offer IUI. 98% (43/44) of those offering IUI also use ovarian stimulation. The most commonly used medications for ovarian stimulation are gonadotrophins (95%), followed by clomiphene citrate (49%) and letrozole (19%). 78% (36/46) of clinics had formally discussed NICE guideline recommendations. 17 clinics (37%) had made some changes to their practices; as a result, four clinics reported a reduction in the number of IUI cycles, six clinics had restricted the indications for IUI, and five clinics had begun informing patients of the guideline recommendations, while two did not specify. Conclusions The majority of clinics were aware of the guideline recommendations. However, only a small proportion of clinics had made significant changes to their practice by reducing the number of IUI cycles or restricting the clinical indications for IUI. The availability of further evidence will assist NICE and clinicians in making recommendations on the use of IUI. There is a need to further explore the reasons for the lack of adherence to the recommendations.